X4 Pharmaceuticals (XFOR) EBT Margin (2018 - 2025)
X4 Pharmaceuticals (XFOR) posted EBT Margin of 931.66% for Q4 2025, up 44.9% on a QoQ basis from 1690.93% in Q3 2025, and up 182727.0% year-over-year from N/an in Q4 2024.
X4 Pharmaceuticals (XFOR) EBT Margin (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals' EBT Margin history runs 4 years deep, the most recent figure standing at 931.66% for Q4 2025.
- Quarterly EBT Margin rose 182727.0% year-over-year to 931.66% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 225.44% (up 122705.0% YoY) and the FY2025 annual result came in at 225.44%, up 122705.0% from the prior year.
- EBT Margin was 931.66% for Q4 2025 at X4 Pharmaceuticals, up from 1690.93% in the prior quarter.
- Across five years, EBT Margin topped out at 16136.94% in Q2 2024 and bottomed at 6550.18% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | -931.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -931.66% |
| Sep 30, 2025 | -1,690.93% |
| Jun 30, 2025 | -1,302.79% |
| Mar 31, 2025 | 1.10% |
| Dec 31, 2024 | -2,758.93% |
| Sep 30, 2024 | -6,550.18% |
| Jun 30, 2024 | 16,136.94% |
| Mar 31, 2020 | -366.33% |
| Dec 31, 2018 | -235.46% |